The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma

about

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma

Item

http://www.wikidata.org/entity/Q36163122

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The REFRACT-LYMA cohort study: ...... ents with mantle cell lymphoma

@ast

The REFRACT-LYMA cohort study: ...... ents with mantle cell lymphoma

@en

type

Item

label

The REFRACT-LYMA cohort study: ...... ents with mantle cell lymphoma

@ast

The REFRACT-LYMA cohort study: ...... ents with mantle cell lymphoma

@en

prefLabel

The REFRACT-LYMA cohort study: ...... ents with mantle cell lymphoma

@ast

The REFRACT-LYMA cohort study: ...... ents with mantle cell lymphoma

@en

P1476

The REFRACT-LYMA cohort study: ...... ents with mantle cell lymphoma

@en

P2093

Catherine Pellat-Deceunynck

http://www.w3.org/2001/XMLSchema#string

Cyrille Touzeau

http://www.w3.org/2001/XMLSchema#string

David Chiron

http://www.w3.org/2001/XMLSchema#string

Henry Jardel

http://www.w3.org/2001/XMLSchema#string

Hervé Maisonneuve

http://www.w3.org/2001/XMLSchema#string

Martine Amiot

http://www.w3.org/2001/XMLSchema#string

Sophie de Visme

http://www.w3.org/2001/XMLSchema#string

Steven le Gouill

http://www.w3.org/2001/XMLSchema#string

P2860

The MOS 36-ltem Short-Form Health Survey (SF-36)

Effectiveness, safety and costs of orphan drugs: an evidence-based review

Mantle cell lymphoma: evolving management strategies

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.

P2888

s12885-016-2844-6

P304

802

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-016-2844-6

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Matthieu Hanf

P577

2016-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1027125209

http://www.w3.org/2001/XMLSchema#string

P698

27737650

http://www.w3.org/2001/XMLSchema#string

P932

5064959

http://www.w3.org/2001/XMLSchema#string